Jounce Therapeutics Inc
JNCE
Get informed when a big investor buys or sells
+ FollowMarket Cap$98.95M
Close$
$3.79
101.8% upside
Current Fair Value
101.8% upsideUndervalued by 101.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $98.95 Million |
|---|---|
| Enterprise Value | $-41,597,260.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.99 |
| Beta | 0.75 |
| Outstanding Shares | 51,676,000 |
Return
| Return on Equity | -27.81% |
|---|---|
| Return on Assets | -23.96% |
| Return on Invested Capital | -27.64% |
Valuation & Multiples
| P/E Ratio | -1.91 |
|---|---|
| PEG | 0 |
| Price to Sales | 1.88 |
| Price to Book Ratio | 0.63 |
| Enterprise Value to Revenue | -0.51 |
| Enterprise Value to EBIT | 0.8 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.24 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jounce Therapeutics Inc
CEO: Richard Murray